
South Korea’s competition regulator has filed against the country’s cosmetics giant Amorepacific Group for 96 million won (US$77,800) over unfair business loan procedures.
According to the country’s Fair Trade Commission (KFTC), Amorepacific Group gave 75 billion won (US$61.2 million) worth of fixed deposits without a fee to Cosvision, which enabled the affiliate to receive a low-interest loan from the Korea Development Bank (KDB).
The loan gave Cosvision an advantage in elevating its business status, which the government saw as an unfair business loan procedure between a conglomerate and its affiliate, and decided to fine the group 9.6 billion won (US$7.8 million), Monday, April 6.
From the fixed deposits obtained, Cosvision was able to receive five loans from KDB, worth a total 60 billion won with a 1.72% to 2.01% interest rate for a year, from August 2016 to August 2017, which is estimated to have created an economic gain worth 139 million won. Without the fixed deposits from the group, Cosvision would have had to pay 2.04% to 2.33% in interest.
Through the loan, Cosvision was able to enhance its production capacity by up to 50% percent and maintain its third-place footing in the domestic cosmetics original equipment and manufacturing (OEM) market as well as acquiring an unfair financial gain via the low interest rates, the KFTC said.
Considering the economic gain from the low interest rate was not significant and most of the loaned money was used to construct a new production line, the regulator did not see it as a fraud case. However, the act was seen as a violation of the country’s fair trade and monopoly regulation act, which led to 48 million won in fines each for Amorepacific and Cosvision.
“The fine could be seen as restraining measures against conglomerates and their unfair support to affiliates, which is aimed to strengthen their competitiveness,” an KFTC official said. “We will heighten surveillance on unfair support measures by conglomerates and take strong action against violators.”
Full Content: Korea Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas